AVBP (ArriVent BioPharma) EBITDA Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is ArriVent BioPharma EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. ArriVent BioPharma's EBITDA for the three months ended in Dec. 2024 was $-23.71 Mil. ArriVent BioPharma's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, ArriVent BioPharma's EBITDA margin for the quarter that ended in Dec. 2024 was 0.00%.

ArriVent BioPharma EBITDA Margin % Historical Data

The historical data trend for ArriVent BioPharma's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArriVent BioPharma EBITDA Margin % Chart

ArriVent BioPharma Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

EBITDA Margin %

ArriVent BioPharma Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBITDA Margin %	Get a 7-Day Free Trial						-	-	-	-	-

Competitive Comparison of ArriVent BioPharma's EBITDA Margin %

For the Biotechnology subindustry, ArriVent BioPharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ArriVent BioPharma's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ArriVent BioPharma's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where ArriVent BioPharma's EBITDA Margin % falls into.

Save Embed

;

Save Embed

;

ArriVent BioPharma EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

ArriVent BioPharma's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-94.308	/	0
	=	%

ArriVent BioPharma's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-23.705	/	0
	=	%

ArriVent BioPharma (NAS:AVBP) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

ArriVent BioPharma EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of ArriVent BioPharma's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

ArriVent BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 Campus Boulevard, Suite 100, Newtown Square, Philadelphia, PA, USA, 19073

Website

https://www.arrivent.com

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.